Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study

BACKGROUND: In our previous study, we investigated the efficacy of ipragliflozin, a sodium-glucose cotransporter (SGLT) 2 inhibitor on diabetic nephropathy in patients with type 2 diabetes and demonstrated that ipragliflozin significantly improved diabetic nephropathy in addition to reducing HbA1c a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Daisuke, Inoue, Kazuyuki, Sumita, Takashi, Hamaguchi, Keiko, Kaneko, Kimie, Yanagisawa, Morifumi, Inukai, Kouichi, Inoue, Ikuo, Noda, Mitsuhiko, Shimada, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089574/
https://www.ncbi.nlm.nih.gov/pubmed/30116437
http://dx.doi.org/10.14740/jocmr3491w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089574/
https://www.ncbi.nlm.nih.gov/pubmed/30116437
http://dx.doi.org/10.14740/jocmr3491w

Ejemplares similares